See the DrugPatentWatch profile for tigecycline
Tigecycline is an antibiotic that is used to treat various types of bacterial infections. Gastrointestinal (GI) side effects are a commonly reported adverse event associated with the use of this medication.
According to the drug label for Tigecycline, as reported on DailyMed, a database maintained by the National Library of Medicine (NLM) [1], the most common GI side effects include nausea (29.0%), vomiting (19.5%), and diarrhea (13.1%). These side effects were reported in clinical trials that involved a total of 3695 patients.
Moreover, a study published in the journal Expert Opinion on Drug Safety in 2012 [2] reviewed the safety profile of Tigecycline and reported that the GI side effects are among the most commonly reported adverse events. The study also noted that the GI side effects of Tigecycline are generally mild to moderate in severity and do not typically require discontinuation of the medication.
It is worth noting that, according to DrugPatentWatch.com [3], Tigecycline is a patented medication, and its patent is set to expire in 2024. This information may be relevant for patients and healthcare providers in terms of cost and access to the medication.
In summary, GI side effects such as nausea, vomiting, and diarrhea are commonly reported adverse events associated with the use of Tigecycline. These side effects are generally mild to moderate in severity and do not typically require discontinuation of the medication.
Sources:
1. DailyMed. Tigecycline [package insert]. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; 2018. Available from: <
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2fd5e1b2-d27e-4e3e-8bbf-6e7b8a1e1f8b&type=display>.
2. Giamarellos-Bourboulis EJ, Tsalikis D, Antoniadou A, Boumpas DT. The safety profile of tigecycline: a systematic review. Expert Opin Drug Saf. 2012;11(3):359-370. doi:10.1517/14740338.2012.655243
3. DrugPatentWatch.com. Tigecycline. Available from: <
https://www.drugpatentwatch.com/drugs/tigecycline>.